Business
IDEAYA Announces Selection of IDE397 Phase 2 Monotherapy Expansion Dose For Global Enrollment Targeting High Priority MTAP-Deletion Solid Tumor Types
Phase 2 monotherapy expansion dose selected for enrollment in high priority MTAP-deletion solid tumor types – NSCLC, bladder and gastroesophageal
About this update from Ideaya Biosciences, Inc.
[{"type":"text","content":"Phase 2 monotherapy expansion dose selected for enrollment in high priority MTAP-deletion solid tumor types – NSCLC, bladder and gastroesophageal cancersObserved partial response by RECIST 1.1 (~40% tumor reduction) at first post-baseline scan in a pre-treated patient having a high priority MTAP-deletion solid tumor typeClinical strategy focused on IDE397 combinations, including with AMG 193, the Amgen MTA-cooperative PRMT5 inhibitor, for which IND-clearance was received in May 2023SOUTH SAN FRANCISCO, Calif., June 12, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced selection of a monotherapy expansion dose for the Phase 2 clinical trial evaluating IDE397 in patients having solid tumors with MTAP deletion. \n\n \n \n \n \n \n \n\n \n\"We have selected a IDE397 Phase 2 monotherapy expansion dose for evaluation in our high-priority solid tumor types with MTAP deletion, including NSCLC, bladder cancer and gastroesophageal cancer. We are in the early stages of enrollment into our global Phase 2 clinical trial monotherapy expansion and have clinical objectives to further define IDE397's monotherapy efficacy in our high priority solid tumor types and to address contribution of components for clinical combinations,\" said Dr. Darrin M. Beaupre, M.D., Ph.D., Chief Medical Officer, IDEAYA Biosciences.\nIDE397 is a potent and selective small molecule inhibitor targeting methionine adenosyltransferase 2a (MAT2A). IDEAYA is clinically evaluating IDE397 as monotherapy in a Phase 1/2 clinical trial in patients having solid tumors with methylthioadenosine phosphorylase (MTAP) deletion, with ongoing enrollment into the global Phase 2 clinical trial. \nIDEAYA is focusing monotherapy expansion cohorts in high-priority tumor types with MTAP deletion, including NSCLC, bladder cancer and gastricesophageal cancer. MTAP deletion is estimated to occur in ~16% of non-small cell lung cancer (NSCLC), ~30% of bladder cancer and ~15% to ~25% of gastricesophageal cancer. These monotherapy indications are being prioritized based on preliminary clinical efficacy and preclinical data demonstrating in vivo efficacy in relevant patient- and/or cell-derived xenograft models and observed endogenous pathway suppression in MTAP deleted tu...